A comprehensive view of Centers for Medicare & Medicaid Services (CMS). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Quest Diagnostics introduces new obstetrics laboratory test panel to screen eligible pregnant women for hepatitis C; in 2021 fewer than 41% of pregnant women were screened for HCV, with screening rates dropping 25% to 35% for women with Medicaid
Published: August 25, 2022 by Fitch Solutions Sector Intelligence
GlobalData forecasts US pharmaceutical sales of prescription/nonprescription drugs to hit US$624B in 2023, but expects few pharmaceutical companies to be left unaffected by Medicare’s planned negotiation on US drug prices, which go into full effect 2026
Published: August 23, 2022 by GlobalData Plc
Moody's: US drug pricing reform in Inflation Reduction Act may have credit-lowering effect on industry; it’s unclear which drugs costs will get negotiated, but potential candidates include drugs from Bristol Myers, Pfizer, Eli Lilly, AbbVie, J&J, Gilead
Published: August 19, 2022 by FiercePharma
BofA: Inflation Reduction Act set to empower Medicare to set prices for 60 drugs by 2029; pricing reforms may not be so bad for pharmaceutical industry, as negotiations could presage 25% price cut for 25 drugs the program spends most on in 2026 and beyond
Published: August 16, 2022 by FiercePharma
Commentary: If Medicare purchased generic drugs at prices charged by Mark Cuban Cost Plus Drug Company in 2020, it would have saved US$3.6B on 77 of 89 drugs, finds report; analysis shows distributing generic drugs can be costlier than making drug itself
Published: June 20, 2022 by Reuters

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count